Literature DB >> 30052597

Combined 68Ga-NOTA-PRGD2 and 18F-FDG PET/CT Can Discriminate Uncommon Meningioma Mimicking High-Grade Glioma.

Deling Li, Jingjing Zhang, Nan Ji, Xiaobin Zhao1, Kun Zheng, Zhen Qiao1, Fang Li, Lixin Lang2, Andrei Iagaru3, Gang Niu2, Zhaohui Zhu, Xiaoyuan Chen2.   

Abstract

OBJECTIVES: Uncommon pathological subtypes of meningioma may present with severe peritumoral brain edema and mimic high-grade glioma (HGG). In a prospective cohort study of Ga-NOTA-PRGD2 PET/CT to evaluate glioma, we occasionally observed that a combination of Ga-NOTA-PRGD2 and F-FDG was able to differentiate these 2 lesion types.
METHODS: From 2013 to 2016, 21 patients suspected of HGG by MRI were recruited for evaluation using Ga-NOTA-PRGD2 PET/CT. Brain F-FDG PET/CT was performed within 3 days for comparison, and the tumor was surgically removed. The PET results were compared with integrin αvβ3 expression and microvascular density quantification of tumor samples.
RESULTS: Of the 21 recruited patients, 5 patients were finally pathologically diagnosed as uncommon meningioma with severe peritumoral brain edema, including chordoid meningioma (n = 1), angiomatous meningioma (n = 1), and mixed angiomatous and microcystic meningioma (n = 3). Sixteen were diagnosed as HGG. All the meningioma lesions (n = 5) exhibited intense and homogeneous Ga-NOTA-PRGD2 uptake with higher SUVmax on Ga-NOTA-PRGD2 PET (1.64-7.86; mean ± SD, 4.23 ± 2.48) than the HGG lesions (0.81-2.99; mean ± SD, 1.57 ± 0.33; P = 0.0047). Moreover, the uptake ratios of Ga-NOTA-PRGD2 over F-FDG, normalized as lg100 * SUVmax (RGD / FDG), in the uncommon meningiomas were significantly higher than those in HGG (1.87 ± 1.36 vs 1.04 ± 0.87, P = 0.0001). A cutoff value of 1.58 was able to discriminate between these lesion types. There were positive correlations among the expression level of integrin αvβ3, microvascular density, and the tumor-to-background ratio derived from Ga-NOTA-PRGD2 PET (P < 0.05).
CONCLUSIONS: This study reveals a specific imaging pattern of uncommon meningioma mimicking HGG, in which Ga-NOTA-PRGD2 PET provided added value to F-FDG PET.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30052597     DOI: 10.1097/RLU.0000000000002233

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  7 in total

1.  Targeting Integrins with Radiolabeled RGD Analogues for Radiotheranostics of Metastatic Radioactive Iodine Nonresponsive Thyroid Cancer: New Avenues in Personalized Medicine.

Authors:  Joanna Klubo-Gwiezdzinska; Xiaoyuan Chen
Journal:  Thyroid       Date:  2020-04       Impact factor: 6.568

Review 2.  Unconventional non-amino acidic PET radiotracers for molecular imaging in gliomas.

Authors:  Francesco Ceci; Andrei Iagaru; R Laudicella; N Quartuccio; G Argiroffi; P Alongi; L Baratto; E Califaretti; V Frantellizzi; G De Vincentis; A Del Sole; L Evangelista; S Baldari; S Bisdas
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-04-13       Impact factor: 10.057

Review 3.  Prediction of Meningioma WHO Grade Using PET Findings: A Systematic Review and Meta-Analysis.

Authors:  K Mariam Slot; Dagmar Verbaan; Dennis R Buis; Linda J Schoonmade; Bart N M Berckel; W Peter Vandertop
Journal:  J Neuroimaging       Date:  2020-11-02       Impact factor: 2.486

Review 4.  Preliminary Clinical Application of RGD-Containing Peptides as PET Radiotracers for Imaging Tumors.

Authors:  Li Li; Xiaoyuan Chen; Jinming Yu; Shuanghu Yuan
Journal:  Front Oncol       Date:  2022-03-02       Impact factor: 6.244

Review 5.  PET Imaging in Neuro-Oncology: An Update and Overview of a Rapidly Growing Area.

Authors:  Antoine Verger; Aurélie Kas; Jacques Darcourt; Eric Guedj
Journal:  Cancers (Basel)       Date:  2022-02-22       Impact factor: 6.639

Review 6.  Molecular Imaging of Angiogenesis in Oncology: Current Preclinical and Clinical Status.

Authors:  Alexandru Florea; Felix M Mottaghy; Matthias Bauwens
Journal:  Int J Mol Sci       Date:  2021-05-24       Impact factor: 5.923

Review 7.  A perspective on the radiopharmaceutical requirements for imaging and therapy of glioblastoma.

Authors:  Julie Bolcaen; Janke Kleynhans; Shankari Nair; Jeroen Verhoeven; Ingeborg Goethals; Mike Sathekge; Charlot Vandevoorde; Thomas Ebenhan
Journal:  Theranostics       Date:  2021-07-06       Impact factor: 11.556

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.